Core Insights - Kronos Bio has nominated KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren's disease, which currently lacks approved treatments addressing its underlying causes [1][3] Group 1: Product Development - KB-7898 is being developed as an orally available therapy for Sjögren's disease, which is characterized by autoantibody production and chronic inflammation [2][5] - The company plans to initiate Investigational New Drug (IND)-enabling studies for KB-7898 in Q4 2024 [1][3] Group 2: Mechanism of Action - p300 is a critical cofactor for immune responses, influencing B cells and T cells, which positions KB-7898 as a potential treatment for other autoimmune diseases in the future [2][3] - Preclinical data indicate that KB-7898 can reduce antibody production in B cells and cytokine production in T cells, potentially impacting the etiology of Sjögren's disease [3][5] Group 3: Preclinical Data - The preclinical data supporting KB-7898's efficacy will be presented at ACR Convergence 2024, highlighting its ability to downregulate proinflammatory cytokines and reduce inflammation in animal models [3][4] - Specific findings include decreased levels of TNFα, IL-23, and IL-17A, as well as reduced joint swelling and clinical scores in rat models [3] Group 4: Market Context - Sjögren's disease affects an estimated 2 to 4 million people in the U.S., with only about 1 million diagnosed due to its heterogeneous symptoms [5] - The disease significantly impacts quality of life and can lead to severe complications, including a 50% increase in all-cause mortality [5] Group 5: Company Overview - Kronos Bio is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting deregulated transcription, with a pipeline that includes three drug candidates [6] - The company operates from San Mateo, California, and has a research facility in Cambridge, Massachusetts [6]

Core Insights - Kronos Bio, Inc. presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, demonstrating its potential to induce cell death in platinum and PARP-inhibitor resistant ovarian cancer models [1][3] - The company is currently conducting a Phase 1/2 clinical trial to evaluate istisociclib's efficacy as a single agent in platinum-resistant high-grade serous ovarian cancer (HGSOC) [2] Preclinical Findings - Istisociclib triggered apoptosis and cell death, evidenced by the accumulation of γH2AX, a marker of DNA damage [4] - The drug disrupted homologous recombination DNA repair by downregulating BRCA1 and RAD51, creating a "BRCAness" phenotype in resistant ovarian cancer cells [4] Clinical Trial Insights - New pharmacokinetic/pharmacodynamic (PK/PD) results from the ongoing trial showed that istisociclib administered at 80mg on a 4 days on/3 days off schedule resulted in a long half-life of approximately 24 hours [4] - Clinical exposures were consistent with efficacious levels observed in preclinical models, leading to sustained downregulation of CDK9-dependent genes in peripheral blood mononuclear cells (PBMCs) [4] Company Overview - Kronos Bio is focused on developing small molecule therapeutics targeting deregulated transcription, a key feature of cancer and other diseases [5] - The company has a preclinical pipeline and two drug candidates, including istisociclib targeting CDK9 and KB-9558 targeting p300 for multiple myeloma [5]

Core Viewpoint - Kronos Bio, Inc. (KRON) has experienced a downtrend with a 5.5% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' improved earnings forecasts [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - KRON's current RSI reading is 23.37, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible trend reversal [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts regarding KRON's earnings estimates, with a 13.9% increase in the consensus EPS estimate over the last 30 days, which often leads to price appreciation [6] - KRON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a strong potential for a near-term turnaround [7]

SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the following upcoming conferences: H.C. Wainwright 26th Annual Global Investment Conference, taking place September 9–11, 2024 in New York, NY Kronos Bio President and Chief Executive Officer, Norbert Bischofberger, Ph.D., will present on Monday, ...

Kronos Bio, Inc. (KRON) has been on a downward spiral lately with significant selling pressure. After declining 23.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whethe ...

The market expects Kronos Bio, Inc. (KRON) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if th ...

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80 ...

— Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — "We are excited for the focused expansion of KB-0742 in platinum-resistant HGSOC. KB-0742 has to date provided prolonged stable disease of over 300 days in one of my platinum-resistant HGSOC patients," said Howard "Skip" A. Burris M.D., president of Sarah Cannon Research Institute (SCRI). "HGSOC patients have limited treatment options after progressing on platinum therapy and KB-0742 brings new possibilities to those battl ...

— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed — SAN MATEO, Calif. and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2 study, KB-0742-1001, a first-in-human, open-label dose escalation and coho ...

Core Insights - Kronos Bio, Inc. presented new data on KB-0742, a small molecule therapeutic targeting CDK9, at the 2024 ASCO Annual Meeting, indicating a manageable safety profile and promising efficacy in treating relapsed or refractory solid tumors and non-Hodgkin lymphoma [1][2][4] Company Overview - Kronos Bio, Inc. is focused on developing small molecule therapeutics that target deregulated transcription, a key factor in cancer and other diseases [7] - The company has a proprietary discovery engine that identifies druggable cofactors within complex transcription factor regulatory networks [7] Drug Development - KB-0742 is currently in a Phase 1/2 study (KB-0742-1001) and has shown a deepening reduction of CDK9-sensitive transcripts at the 80mg dose compared to the 60mg dose [2][9] - The ongoing study includes 103 patients with transcription factor fusion or MYC-driven tumors, with a median of three prior treatments [6] - The 80mg four-days-on, three-days-off dosing schedule is expected to enhance efficacy, with enrollment for the expansion cohort anticipated to begin in Q3 2024 [3][5] Efficacy and Safety Data - Preliminary data from the study indicated manageable mild to moderate adverse events, with no grade 3/4 neutropenia observed [6] - Patients treated with KB-0742 exhibited anti-tumor activity, including stable disease responses of 71 days for a non-small-cell lung cancer patient and over 195 days for a platinum-resistant ovarian cancer patient [6] Future Expectations - The company is optimistic about the potential increased patient benefit from the 80mg dosing schedule, supported by pharmacokinetic modeling showing a greater than ten-fold increase in time above a preclinically determined efficacy threshold compared to the 60mg schedule [5][6]